|
1
|
Geraldino-Pardilla L and Bathow JM:
Management of rheumatoid arthritis: synovitis. Rheumatology.
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH:
(6th). (Philadelphia, PA). Mosby Elsevier. 802–807. 2015.
|
|
2
|
Smolen JS, Landewé R, Breedveld FC,
Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J,
Schoels M, et al: EULAR recommendations for the management of
rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Ann Rheum Dis. 69:964–975.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh JA, Furst DE, Bharat A, Curtis JR,
Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, et al:
2012 update of the 2008 American College of Rheumatology
recommendations for the use of disease-modifying antirheumatic
drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care Res (Hoboken). 64:625–639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patrono C: Non-steroidal anti-inflammatory
drugs. Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt
ME and Weisman MH: (6th). (Philadelphia, PA). Mosby Elsevier.
415–422. 2015.PubMed/NCBI
|
|
5
|
Saag K and Buttgereit F: Systemic
glucocorticoids. Rheumatology. Hochberg MC, Silman AJ, Smolen JS,
Weinblatt ME and Weisman MH: (6th). (Philadelphia, PA). Mosby
Elsevier. 423–431. 2015.
|
|
6
|
Buttgereit F, da Silva JA, Boers M,
Burmester GR, Cutolo M, Jacobs J, Kirwan J, Köhler L, Van Riel P,
Vischer T, et al: Standardised nomenclature for glucocorticoid
dosages and glucocorticoid treatment regimens: current questions
and tentative answers in rheumatology. Ann Rheum Dis. 61:718–722.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grigor C, Capell H, Stirling A, McMahon
AD, Lock P, Vallance R, Kincaid W and Porter D: Effect of a
treatment strategy of tight control for rheumatoid arthritis (the
TICORA study): a single-blind randomised controlled trial. Lancet.
364:263–269. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnsen AK and Weinblatt ME: Methotrexate.
Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and
Weisman MH: (6th). (Philadelphia, PA). Mosby Elsevier. 443–449.
2015.PubMed/NCBI
|
|
9
|
McInnes IB, Jacobs JWG, Woodburn J and van
Laar JM: Treatment of rheumatoid arthritis. Eular Compendium on
Rheumatic Diseases. Bijlsma JW: BMJ Publishing Group and European
League against Rheumatism. 83–86. 2009.
|
|
10
|
Battistone MJ and Williams HJ:
Disease-modifying antirheumatic drugs 3: methotrexate.
Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and
Weisman MH: (4th). (Philadelphia, PA). Mosby Elsevier. 449–457.
2008.
|
|
11
|
Johnston A, Gudjonsson JE, Sigmundsdottir
H, Ludviksson BR and Valdimarsson H: The anti-inflammatory action
of methotrexate is not mediated by lymphocyte apoptosis, but by the
suppression of activation and adhesion molecules. Clin Immunol.
114:154–163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cutolo M, Sulli A, Pizzorni C, Seriolo B
and Straub RH: Anti-inflammatory mechanisms of methotrexate in
rheumatoid arthritis. Ann Rheum Dis. 60:729–735. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Chen Z, Yang S, Wang Y, Yu L,
Zhang B, Rao Z, Gao J and Tu S: NMR-based metabolomic analysis for
identifying serum biomarkers to evaluate methotrexate treatment in
patients with early rheumatoid arthritis. Exp Ther Med. 4:165–171.
2012.PubMed/NCBI
|
|
14
|
Kremer JM, Alarcón GS, Lightfoot RW Jr,
Willkens RF, Furst DE, Williams HJ, Dent PB and Weinblatt ME:
American College of Rheumatology: Methotrexate for rheumatoid
arthritis. Suggested guidelines for monitoring liver toxicity.
Arthritis Rheum. 37:316–328. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cannon G, Sciff M, Strand V and Holden W:
Hepatic adverse events and other toxicity during treatment with
leflunomide, methotrexate, other disease-modifying antirheumatic
drugs (DMARDs), and combination DMARD therapy: Comparison to NSAIDS
alone and adjustment for comorbidities cathegory. Arthritis Rheum.
46(Suppl): Abs S357. 2002.
|
|
16
|
O'Dell JR: Methotrexate, Leflunomide, and
Combination Therapies. Kelley's Textbook of Rheumatology. Ruddy S:
(Philadelphia, PA). WB Saunders Company. 906–910. 2005.
|
|
17
|
Hampson R, Madhok R and McInnes I:
Methotrexate and sulfasalazine combination therapy (MASCOT) is more
effective than either drug alone in patients with a sub-optimal
response to sulfasalazine monotherapy: A double blind placebo
randomised controlled trial (RCT). Ann Rheum Dis. 64(suppl 3):
456–457. 2005.
|
|
18
|
Haraoui B: Leflunomide. Rheumatology.
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH:
(6th). (Philadelphia, PA). Mosby Elsevier. 451–445. 2015.
|
|
19
|
Keystone E and Haraoui B:
Disease-modifying antirheumatic drugs 4: leflunomide. Rheumatology.
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH:
(4th). (Philadelphia, PA). Mosby Elsevier. 461–468. 2008.
|
|
20
|
Capell HA and Madhok R: Disease-modifying
antirheumatic drugs 2: sulfasalazine. Rheumatology. Hochberg MC,
Silman AJ, Smolen JS, Weinblatt ME and Weisman MH: (4th).
(Philadelphia, PA). Mosby Elsevier. 437–445. 2008.PubMed/NCBI
|
|
21
|
Bykerk V: Non-immunosuppressive
disease-modifying antirheumatic drugs. Rheumatology. Hochberg MC,
Silman AJ, Smolen JS, Weinblatt ME and Weisman MH: (6th).
(Philadelphia, PA). Mosby Elsevier. 436–437. 2015.PubMed/NCBI
|
|
22
|
Gordon DA and Klinkhoff AV: Second Line
Agents. Kelley's Textbook of Rheumatology. Ruddy S: (Philadelphia,
PA). WB Saunders Company. 877–899. 2005.
|
|
23
|
Fleischmann RM: Biologic therapy in
rheumatoid arthritis. Rheumatol News. (suppl 1): 3–4. 2002.
|
|
24
|
Choy EH and Panayi GS: Cytokine pathways
and joint inflammation in rheumatoid arthritis. N Engl J Med.
344:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dinarello CA and Moldawer LL:
Proinflammatory and antiinflammatory cytokines in rheumatoid
arthritis: A primer for clinicians (2nd). Thousand Oaks, CA: Amgen,
Inc. 2000.
|
|
26
|
Lam J, Abu-Amer Y, Nelson CA, Fremont DH,
Ross FP and Teitelbaum SL: Tumour necrosis factor superfamily
cytokines and the pathogenesis of inflammatory osteolysis. Ann
Rheum Dis. 61(Suppl 2): ii82–ii83. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maini R, St Clair EW, Breedveld F, Furst
D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M,
et al: ATTRACT Study Group: Infliximab (chimeric anti-tumour
necrosis factor alpha monoclonal antibody) versus placebo in
rheumatoid arthritis patients receiving concomitant methotrexate: A
randomised phase III trial. Lancet. 354:1932–1939. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maini RN, Breedveld FC, Kalden JR, Smolen
JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D,
Marsters PA, et al: Anti-Tumor Necrosis Factor Trial in Rheumatoid
Arthritis with Concomitant Therapy Study Group: Sustained
improvement over two years in physical function, structural damage,
and signs and symptoms among patients with rheumatoid arthritis
treated with infliximab and methotrexate. Arthritis Rheum.
50:1051–1065. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smolen JS, Han C, Bala M, Maini RN, Kalden
JR, van der Heijde D, Breedveld FC, Furst DE and Lipsky PE: ATTRACT
Study Group: Evidence of radiographic benefit of treatment with
infliximab plus methotrexate in rheumatoid arthritis patients who
had no clinical improvement: A detailed subanalysis of data from
the anti-tumor necrosis factor trial in rheumatoid arthritis with
concomitant therapy study. Arthritis Rheum. 52:1020–1030. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nam JL, Ramiro S, Gaujoux-Viala C, Takase
K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS and Buch
MH: Efficacy of biological disease-modifying antirheumatic drugs: a
systematic literature review informing the 2013 update of the EULAR
recommendations for the management of rheumatoid arthritis. Ann
Rheum Dis. 73:516–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weinblatt ME, Keystone EC, Furst DE,
Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA and
Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor
alpha monoclonal antibody, for the treatment of rheumatoid
arthritis in patients taking concomitant methotrexate: The ARMADA
trial. Arthritis Rheum. 48:35–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van de Putte LB, Atkins C, Malaise M, Sany
J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S,
Dougados M, et al: Efficacy and safety of adalimumab as monotherapy
in patients with rheumatoid arthritis for whom previous disease
modifying antirheumatic drug treatment has failed. Ann Rheum Dis.
63:508–516. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Keystone EC, Kavanaugh AF, Sharp JT,
Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA and Chartash EK:
Radiographic, clinical, and functional outcomes of treatment with
adalimumab (a human anti-tumor necrosis factor monoclonal antibody)
in patients with active rheumatoid arthritis receiving concomitant
methotrexate therapy: A randomized, placebo-controlled, 52-week
trial. Arthritis Rheum. 50:1400–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weinblatt ME, Keystone EC, Furst DE,
Kavanaugh AF, Chartash EK and Segurado OG: Long term efficacy and
safety of adalimumab plus methotrexate in patients with rheumatoid
arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 65:753–759.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Breedveld FC, Weisman MH, Kavanaugh AF,
Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL and
Spencer-Green GT: The PREMIER study: A multicenter, randomized,
double-blind clinical trial of combination therapy with adalimumab
plus methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not
had previous methotrexate treatment. Arthritis Rheum. 54:26–37.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keystone EC, Genovese MC, Klareskog L,
Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J,
et al: Golimumab, a human antibody to TNF-α given by monthly
subcutaneous injections, in active rheumatoid arthritis despite
methotrexate: the GO-FORWARD Study. Ann Rheum Dis. 68:789–796.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kay J and Rahman MU: Golimumab: A novel
human anti-TNF-α monoclonal antibody for the treatment of
rheumatoid arthritis, ankylosing spondylitis, and psoriatic
arthritis. Core Evid. 4:159–170. 2009. View Article : Google Scholar
|
|
38
|
McDonnell T, Ioannou Y and Rahman A:
PEGylated drugs in rheumatology - why develop them and do they
work? Rheumatology (Oxford). 53:391–396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Keystone E, Heijde D, Mason D Jr, Landewé
R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, et
al: Certolizumab pegol plus methotrexate is significantly more
effective than placebo plus methotrexate in active rheumatoid
arthritis: Findings of a fifty-two-week, phase III, multicenter,
randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheum. 58:3319–3329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Smolen J, Landewé RB, Mease P, Brzezicki
J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M,
Burmester GR, et al: Efficacy and safety of certolizumab pegol plus
methotrexate in active rheumatoid arthritis: The RAPID 2 study. A
randomised controlled trial. Ann Rheum Dis. 68:797–804. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fleischmann R, Vencovsky J, van
Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek
HP, Innes A and Strand V: Efficacy and safety of certolizumab pegol
monotherapy every 4 weeks in patients with rheumatoid arthritis
failing previous disease-modifying antirheumatic therapy: The
FAST4WARD study. Ann Rheum Dis. 68:805–811. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Klareskog L, van der Heijde D, de Jager
JP, Gough A, Kalden J, Malaise M, Mola Martín E, Pavelka K, Sany J,
Settas L, et al: TEMPO (Trial of Etanercept and Methotrexate with
Radiographic Patient Outcomes) study investigators: Therapeutic
effect of the combination of etanercept and methotrexate compared
with each treatment alone in patients with rheumatoid arthritis:
Double-blind randomised controlled trial. Lancet. 363:675–681.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Emery P, Breedveld F, van der Heijde D,
Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS and
Freundlich B: Combination of Methotrexate and Etanercept in Early
Rheumatoid Arthritis Trial Group: Two-year clinical and
radiographic results with combination etanercept-methotrexate
therapy versus monotherapy in early rheumatoid arthritis: a
two-year, double-blind, randomized study. Arthritis Rheum.
62:674–682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cañete JD and Pablos JL: Biologic therapy
in rheumatoid arthritis. Curr Top Med Chem. 13:752–759. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ramiro S, Gaujoux-Viala C, Nam JL, Smolen
JS, Buch M, Gossec L, van der Heijde D, Winthrop K and Landewé R:
Safety of synthetic and biological DMARDs: a systematic literature
review informing the 2013 update of the EULAR recommendations for
management of rheumatoid arthritis. Ann Rheum Dis. 73:529–535.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leombruno JP, Einarson TR and Keystone EC:
The safety of anti-tumour necrosis factor treatments in rheumatoid
arthritis: meta and exposure-adjusted pooled analyses of serious
adverse events. Ann Rheum Dis. 68:1136–1145. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rueda Gotor J and Blanco Alonso R:
Tocilizumab in rheumatoid arthritis. Reumatol Clin. 6S3:S29–S32.
2011.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jones G, Sebba A, Gu J, Lowenstein MB,
Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T,
et al: Comparison of tocilizumab monotherapy versus methotrexate
monotherapy in patients with moderate to severe rheumatoid
arthritis: the AMBITION study. Ann Rheum Dis. 69:88–96. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kaufmann J, Feist E, Roske AE and Schmidt
WA: Monotherapy with tocilizumab or TNF-alpha inhibitors in
patients with rheumatoid arthritis: efficacy, treatment
satisfaction, and persistence in routine clinical practice. Clin
Rheumatol. 32:1347–1355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Smolen JS, Landewé R, Breedveld FC, Buch
M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam
J, et al: EULAR recommendations for the management of rheumatoid
arthritis with synthetic and biological disease-modifying
antirheumatic drugs: 2013 update. Ann Rheum Dis. 73:492–509.
2014.
|
|
51
|
Meier FM, Frerix M, Hermann W and
Müller-Ladner U: Current immunotherapy in rheumatoid arthritis.
Immunotherapy. 5:955–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gabay C: Cytokine neutralizers:
interleukin-1 inhibitors. Rheumatology. Hochberg MC, Silman AJ,
Smolen JS, Weinblatt ME and Weisman MH: (6th). (Philadelphia, PA).
Mosby Elsevier. 479–483. 2015.
|
|
53
|
Choi EH: T-cell costimulation and other
directed therapies. Rheumatology. Hochberg MC, Silman AJ, Smolen
JS, Weinblatt ME and Weisman MH: (6th). (Philadelphia, PA). Mosby
Elsevier. 468–470. 2015.
|
|
54
|
Caporali R, Bugatti S, Cavagna L,
Antivalle M and Sarzi-Puttini P: Modulating the co-stimulatory
signal for T cell activation in rheumatoid arthritis: Could it be
the first step of the treatment? Autoimmun Rev. 13:49–53. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Weinblatt ME, Schiff M, Valente R, van der
Heijde D, Citera G, Zhao C, Maldonado M and Fleischmann R:
Head-to-head comparison of subcutaneous abatacept versus adalimumab
for rheumatoid arthritis: Findings of a phase IIIb, multinational,
prospective, randomized study. Arthritis Rheum. 65:28–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Edwards JC and Cambridge G: Sustained
improvement in rheumatoid arthritis following a protocol designed
to deplete B lymphocytes. Rheumatology (Oxford). 40:205–211. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Edwards JC, Szczepanski L, Szechinski J,
Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM and Shaw T:
Efficacy of B-cell-targeted therapy with rituximab in patients with
rheumatoid arthritis. N Engl J Med. 350:2572–2581. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Emery P, Fleischmann R,
Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A,
Racewicz AJ, van Vollenhoven RF, Li NF, et al: The efficacy and
safety of rituximab in patients with active rheumatoid arthritis
despite methotrexate treatment: results of a phase IIB randomized,
double-blind, placebo-controlled, dose-ranging trial. Arthritis
Rheum. 54:1390–1400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vital EM, Dass S and Emery P: B-cell
depletion. Rheumatology. Hochberg MC, Silman AJ, Smolen JS,
Weinblatt ME and Weisman MH: (6th). (Philadelphia, PA). Mosby
Elsevier. 472–477. 2015.
|
|
60
|
Van Vollenhoven RF: Kinase inhibition: a
new therapeutic principle in rheumatology. Rheumatology. Hochberg
MC, Silman AJ, Smolen JS, Weinblatt ME and Weisman MH: (6th).
(Philadelphia, PA). Mosby Elsevier. 511–516. 2015.PubMed/NCBI
|
